ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChemotherapy-induced toxicities represent a major clinical challenge in gastric cancer treatment, with limited effective management strategies. Emerging evidence suggests that gut microbiota dysbiosis is a key driver of these adverse effects, while traditional Chinese medicine (TCM) shows potential in modulating gut microbial composition. This review aims to systematically summarize the molecular mechanisms and clinical evidence of TCM in alleviating chemotherapy-induced toxicities in gastric cancer through gut microbiota regulation and to identify current research gaps.
methodsA systematic literature search was conducted using SCI-indexed studies, primarily published in recent years, with inclusion of foundational studies where necessary. The review focused on chemotherapy-induced gut microbiota dysbiosis and its role in toxicity, as well as the effects of TCM-including polysaccharides, flavonoids, and herbal formulations-on microbial composition, metabolic products such as short-chain fatty acids (SCFA), LPS, and inflammatory signaling pathways.
resultsGut microbiota dysbiosis contributes to systemic inflammation primarily through activation of the LPS/TLR4/NF-κB/NLRP3 inflammasome pathway and reduced SCFA-mediated histone deacetylase inhibition. TCM regulates gut microbiota through a "structure-metabolite-immune" framework, restoring microbial diversity, increasing SCFA production, reducing LPS levels, and suppressing inflammatory signaling. Clinically, oral and injectable TCM formulations such as SFI and HCS have shown moderate- to high-quality evidence in improving immune function, alleviating myelosuppression, and reducing gastrointestinal toxicities, whereas evidence for external therapies remains limited.
conclusionTCM represents a promising microbiota-targeted strategy for mitigating chemotherapy-induced toxicities in gastric cancer. Future studies should focus on STING signaling and the gut-brain axis, conduct large-scale randomized controlled trials (RCTs), and develop microbiota-based personalized TCM interventions to advance evidence-based integrative oncology.
Indexed as
Identifiers
42821123What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.